ClinicalTrials.gg
RecruitingNCT04885985Updated Aug 1, 2024

ACOART BTK RENEW:A Post Market Clinical Study

An interventional study of DEB catheter in Peripheral Artery Disease, sponsored by Acotec Scientific Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by Acotec Scientific Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Dec 2021; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
107
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.

Planned enrollment
41st of 53
107 · median 167
Started
2021
with 6 others
No phase
34 of 80
13 open now
Primary completion
2024-08
later than 5 of 33 live
Registered
35th of 80
by date
Lead sponsor
7 of 80
Acotec Scientific Co., Ltd

Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 41st largest by planned enrollment of the 53 interventional ones that give a count, is one of 7 that started in 2021, is one of 34 with no phase, reaches primary completion later than 5 of the 33 other live ones, and was the 35th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Peripheral Arterial Disease with a site in China, or all of them as a file.
02

Study summary

The objective of this prospective, multi-center, single arm study is to obtain further data on the safety and performance of the Acotec Litos\&Tulip Drug-coated Balloon catheters in the treatment of lesions in below-the-knee artery.

03

Conditions studied

  • Peripheral Artery Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Age ≥18 years old and ≤75 years old
    1. Rutherford clinical category classification:3,4 or 5
    1. Significant stenosis (≥70%) or occlusions of de-novo or restenotic lesion(s) located in below-the-knee arteries which distal bloodflow is patent.
    1. Reference vessel diameter is between 2 mm and 4 mm
    1. Subject has provided written prior to participation , understands the purpose of this trail and agrees to comply with all protocol-specified examinations and follow-up appointments.

Exclusion criteria

Exclusion Criteria:

    1. Plasma rate \<30 mL/min
    1. Acute vessel occlusion or acute thrombosis in target lesion
    1. Planned amputation on the target limb
    1. Subjects confined to bed that are completely non-ambulatory.
    1. Thrombolytic therapy or surgical procedure on the target limb within 6 weeks prior to enrollment.
    1. \< 5 year.
    1. Cumulative length of 100% occluded target lesion(s)>150 mm
    1. In-stent restenosis within the target lesion, or the distance between the target lesions and the stent was less than 20 mm
    1. History of stroke within 90 days prior to enrollment
    1. Known allergy to contrast agents, antiplatelet, anticoagulant, or thrombolytic therapy
    1. Uncorrectable bleeding diathesis
    1. The lesion of the inflow pathway cannot be identified due to the complete occlusion of the P3 segment of the popliteal artery
    1. Pregnant or breastfeeding female subjects
    1. Ability to cross a guidewire through target lesion
    1. Patients who have participated in clinical trials of other medical devices or drugs during the same period
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (estimated)

Study arms

  • Experimental
    DEB catheter

    Use DEB catheter to treat the stenosis or occlusion in below popliteal artery of experimental arm

    Device: DEB catheter

Interventions

  • DeviceDEB catheter

    Trade name of DEB catheter: AcoArt Tulip (0.018") or AcoArt Litos (0.014")

06

What researchers measure

Primary outcomes

  1. Primary Patency

    Primary patency rate is defined as freedom from clinically-driven target lesion revascularisation (CD-TLR) , restenosis as determined by duplex ultrasound (DUS) or digital subtraction angiography (DSA) or major target limb amputation.

    Time frame: 6 month

Secondary outcomes

  1. Major adverse event (MAE) rate

    Defined as a composite rate of all-cause death, target limb major amputation and CD-TLR

    Time frame: 30 days

  2. Patency rate

    Defined as freedom from clinically-driven target lesion revascularisation (CD-TLR) , restenosis as determined by duplex ultrasound (DUS) or digital subtraction angiography (DSA) or major target limb amputation.

    Time frame: 12 months,24 months,36 months,48 months ,60 months

  3. Rate of major target limb amputation

    A major adverse limb event is defined as above-ankle amputation of the treated limb

    Time frame: 12 months,24 months,36 months,48 months ,60 months

  4. Rate of All-cause mortality

    All-cause mortality at 12, 24, 36, 48, 60 months post procedure

    Time frame: 12 months,24 months,36 months,48 months ,60 months

  5. Rate of clinically-driven target vessel revascularization (CD-TVR)

    Clinically-driven target vessel revascularization (CD-TVR) at 12, 24, 36, 48, 60 months post procedure

    Time frame: 12 months,24 months,36 months,48 months ,60 months

  6. Rate of clinically-driven target lesion revascularization (CD-TLR)

    Clinically-driven target lesion revascularization (CD-TLR) at 12, 24, 36, 48, 60 months post procedure

    Time frame: 12 months,24 months,36 months,48 months ,60 months

  7. Rate of ulcer healing

    Ulcer healed or not; if not, improving, stagnant,worsening

    Time frame: 12 months,24 months,36 months,48 months ,60 months

  8. Rate of distal embolization

    Rate of distal embolization defined as occurrence significant distal embolization in target limb through the end of the procedure

    Time frame: through procedure completion

07

Study locations

1 of 1 sites recruiting
  • Chui Yang Liu Hospital affiliated to Tsinghua University
    Beijing, Beijing 100021, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Aug 2024, 31 months after the start.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 31 months is above that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2021
First posted
May 13, 2021
StartActual
Dec 31, 2021
Primary completionEst.
Aug 1, 2024
CompletionEst.
Apr 1, 2027
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04885985
Lead sponsor
Acotec Scientific Co., Ltd
Responsible party
Sponsor
First posted
May 13, 2021
Start date
Dec 31, 2021
Primary completion
Aug 1, 2024 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Aug 1, 2024

Study contacts

Zhuang Baixi
Contact
zhuangbaixi@163.com
010-62835122
Zhuang Baixi
principal investigator · Xiyuan Hospital of China Academy of Chinese Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion